← Back

Wire · opportunities

Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor ...

Published

10 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at businesswire.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

The U.S. FDA approved Bayer's SUNHARBO (asundexian) 50 mg tablets as the first Factor XIa inhibitor to reduce the risk of secondary stroke in adults with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack, in combination with antiplatelet therapy. Clinical trial data showed a 26% reduction in ischemic stroke risk compared to placebo, with a similar rate of major bleeding.

This Wire brief sits within Fusion42's coverage of Medtech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You can now offer a first-in-class stroke prevention treatment that lowers recurrent stroke risk without increasing major bleeding. Neurology and cardiology founders should explore partnerships or integration around this novel Factor XIa inhibitor to address an unmet need in secondary stroke care.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Medtechstroke-preventionfda-approvalcardiovascularfactor-xia-inhibitorclinical-trialbayer